Casting a Broader Net
Can a new combination of blood tests for pancreatic cancer improve detection rates for a disease in which early diagnosis is notoriously difficult?
Luke Turner | | Quick Read
Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) are poor – only 8.5 percent of patients diagnosed with the most common form of pancreatic cancer survive past five years. That’s approximately the same chance of survival as those diagnosed with the same disease 30 years ago… so why haven’t we seen any improvement?
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine